ECSP11011288A - Derivados de indol como antagonistas del receptor crth2 - Google Patents

Derivados de indol como antagonistas del receptor crth2

Info

Publication number
ECSP11011288A
ECSP11011288A EC2011011288A ECSP11011288A ECSP11011288A EC SP11011288 A ECSP11011288 A EC SP11011288A EC 2011011288 A EC2011011288 A EC 2011011288A EC SP11011288 A ECSP11011288 A EC SP11011288A EC SP11011288 A ECSP11011288 A EC SP11011288A
Authority
EC
Ecuador
Prior art keywords
crth2
anthogonist
indol
derivatives
receiver
Prior art date
Application number
EC2011011288A
Other languages
English (en)
Inventor
Carl Berthelette
John Colucci
Michael Boyd
Karine Villeneuve
Joey Methot
Original Assignee
Merck Sharp & Dohme
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Frosst Canada Ltd filed Critical Merck Sharp & Dohme
Publication of ECSP11011288A publication Critical patent/ECSP11011288A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona nuevos compuestos que son antagonistas del receptor CRTH2. Los compuestos de la presente invención son útiles para el tratamiento de diversas enfermedades y trastornos mediados por prostaglandina; por consiguiente, la presente invención proporciona un método para el tratamiento de enfermedades mediadas por prostaglandina que usa los compuestos novedosos que se describen en este documento, así como composiciones farmacéuticas que los contienen.
EC2011011288A 2009-02-24 2011-08-24 Derivados de indol como antagonistas del receptor crth2 ECSP11011288A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15496809P 2009-02-24 2009-02-24

Publications (1)

Publication Number Publication Date
ECSP11011288A true ECSP11011288A (es) 2011-10-31

Family

ID=42046150

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011288A ECSP11011288A (es) 2009-02-24 2011-08-24 Derivados de indol como antagonistas del receptor crth2

Country Status (36)

Country Link
US (2) US8394819B2 (es)
EP (2) EP2492267B1 (es)
JP (1) JP4989786B1 (es)
KR (2) KR101276530B1 (es)
CN (1) CN102333771B (es)
AR (1) AR075597A1 (es)
AU (1) AU2010218209B2 (es)
BR (1) BRPI1008906B1 (es)
CA (1) CA2752981C (es)
CL (1) CL2011002056A1 (es)
CO (1) CO6410295A2 (es)
CR (1) CR20110455A (es)
DK (1) DK2401269T3 (es)
DO (1) DOP2011000271A (es)
EA (1) EA021076B1 (es)
EC (1) ECSP11011288A (es)
ES (2) ES2529420T3 (es)
HN (1) HN2011002272A (es)
HR (1) HRP20140384T1 (es)
IL (1) IL214342A0 (es)
MA (1) MA33134B1 (es)
MX (1) MX2011008869A (es)
MY (1) MY152062A (es)
NI (1) NI201100162A (es)
NZ (1) NZ594767A (es)
PE (1) PE20120056A1 (es)
PL (1) PL2401269T3 (es)
PT (1) PT2401269E (es)
RS (1) RS53268B (es)
SG (1) SG173775A1 (es)
SI (1) SI2401269T1 (es)
TN (1) TN2011000382A1 (es)
TW (2) TWI454474B (es)
UA (1) UA105039C2 (es)
WO (1) WO2010099039A1 (es)
ZA (1) ZA201105767B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031184A1 (en) * 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
EP2346865B1 (en) * 2008-09-22 2015-07-15 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
KR20130133219A (ko) 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
MX338516B (es) * 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
US8592383B2 (en) 2011-06-17 2013-11-26 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators
US20130072470A1 (en) 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
CN103450218B (zh) * 2012-05-29 2015-12-23 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类三并环衍生物
US9290454B2 (en) 2012-10-01 2016-03-22 Merck Sharp & Dohme Corp. Substituted isoquinolines as CRTH2 receptor modulators
WO2014060596A1 (en) * 2012-10-18 2014-04-24 Zach System S.P.A. Process for preparing indole derivatives
MX384987B (es) 2014-03-17 2025-03-14 Idorsia Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores de receptor de prostaglandina d2.
EP3119780B1 (en) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
PT3277722T (pt) 2015-04-02 2021-10-06 Intervet Int Bv Anticorpos para recetor alfa da interleucina-4 canina
WO2017005764A1 (en) * 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycloketone intermediates of crth2 antagonists
WO2017005766A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycic alcohol intermediates of crth2 antagonists
WO2017005759A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make azaindole derivatives
US11091806B2 (en) * 2015-07-23 2021-08-17 Merck Sharp & Dohme Corp. Genetic markers associated with response to CRTH2 receptor antagonists
JP6833852B2 (ja) 2015-09-15 2021-02-24 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 結晶形
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913989QA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12071666B2 (en) 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
CA3161496A1 (en) 2019-12-20 2021-06-24 Mohamad Morsey Bispecific caninized antibodies for treating atopic dermatitis
JP2024532159A (ja) 2021-08-20 2024-09-05 インターベット インターナショナル ベー． フェー． アトピー性皮膚炎を治療するための融合タンパク質

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en) 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
WO2004103970A1 (en) * 2003-05-20 2004-12-02 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
NZ550365A (en) * 2004-03-11 2010-09-30 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
TW200605885A (en) 2004-07-29 2006-02-16 Threshold Pharmaceuticals Inc Multicyclic lonidamine analogs
GB0427381D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
RU2404163C2 (ru) * 2004-12-27 2010-11-20 Актелион Фармасьютиклз Лтд Производные 2,3,4,9-тетрагидро-1h-карбазола в качестве антагонистов рецептора crth2
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
EP1915372B1 (en) * 2005-08-12 2013-11-20 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
CA2658986C (en) * 2006-08-07 2014-11-25 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
AU2009295229B2 (en) * 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
WO2010031184A1 (en) * 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
EP2346865B1 (en) 2008-09-22 2015-07-15 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
WO2010085820A2 (en) 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Tricyclic compounds as antagonists of prostaglandin d2 receptors

Also Published As

Publication number Publication date
US9023864B2 (en) 2015-05-05
ZA201105767B (en) 2012-04-25
AR075597A1 (es) 2011-04-20
EA021076B1 (ru) 2015-03-31
DOP2011000271A (es) 2011-10-15
TW201402573A (zh) 2014-01-16
HRP20140384T1 (en) 2014-05-23
BRPI1008906B1 (pt) 2019-10-15
UA105039C2 (uk) 2014-04-10
BRPI1008906A2 (pt) 2016-03-15
MX2011008869A (es) 2011-12-16
US8394819B2 (en) 2013-03-12
HN2011002272A (es) 2014-02-24
RS53268B (sr) 2014-08-29
EP2492267A1 (en) 2012-08-29
DK2401269T3 (da) 2014-04-28
JP4989786B1 (ja) 2012-08-01
AU2010218209B2 (en) 2012-12-13
CL2011002056A1 (es) 2012-04-09
CN102333771A (zh) 2012-01-25
EP2401269B1 (en) 2014-01-29
CR20110455A (es) 2012-01-10
SG173775A1 (en) 2011-09-29
EP2401269A1 (en) 2012-01-04
IL214342A0 (en) 2011-09-27
EP2492267B1 (en) 2014-11-26
AU2010218209A1 (en) 2011-08-25
ES2450594T3 (es) 2014-03-25
US20130150398A1 (en) 2013-06-13
TWI454474B (zh) 2014-10-01
TWI444381B (zh) 2014-07-11
ES2529420T3 (es) 2015-02-19
CA2752981A1 (en) 2010-09-02
HK1160465A1 (en) 2012-08-17
KR20130028156A (ko) 2013-03-18
NZ594767A (en) 2013-05-31
US20100234415A1 (en) 2010-09-16
TN2011000382A1 (en) 2013-03-27
KR101275980B1 (ko) 2013-06-17
KR101276530B1 (ko) 2013-06-18
TW201035096A (en) 2010-10-01
MA33134B1 (fr) 2012-03-01
CN102333771B (zh) 2014-03-19
NI201100162A (es) 2012-02-01
WO2010099039A1 (en) 2010-09-02
SI2401269T1 (sl) 2014-04-30
EA201171081A1 (ru) 2012-02-28
PL2401269T3 (pl) 2014-07-31
PT2401269E (pt) 2014-03-11
CO6410295A2 (es) 2012-03-30
PE20120056A1 (es) 2012-02-05
MY152062A (en) 2014-08-15
JP2012517484A (ja) 2012-08-02
CA2752981C (en) 2013-11-12
KR20110107395A (ko) 2011-09-30

Similar Documents

Publication Publication Date Title
ECSP11011288A (es) Derivados de indol como antagonistas del receptor crth2
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
MX2013006634A (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
UY32574A (es) Antagonistas del receptor cxcr3
UY32996A (es) Antagonistas del receptor crth2 basados en indol
UY34530A (es) Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1)
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
UY33896A (es) ?moduladores del receptor de glucagón?.
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
ECSP10010518A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
JO3202B1 (ar) مركبات 4- فينيل- بيريدين بها استبدال لعلاج الامراض ذات الصلة بمستقبل nk-1
ECSP11010885A (es) Heteroarilos sustituidos
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
DOP2013000195A (es) Compuestos novedosos en base a ureas asimetricas, y usos medicos de los mismos
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
DOP2016000211A (es) Pirazinas moduladoras de gpr6
UY33824A (es) ?moduladores del receptor del glucagón?.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
AR073708A1 (es) Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
UY32385A (es) Amidas de pirazinona sustituida
SV2011003821A (es) Compuestos de fenantrenona, composiciones y metodos
CU20130159A7 (es) Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina